Signet Healthcare Partners (“Signet”) has announced the successful sale of its portfolio company, Paragonix Technologies (“Paragonix”), to global medical technology leader Getinge. Paragonix, renowned for its advancements in organ transplantation and preservation, marks a significant acquisition for Getinge, enhancing its…
Contraline, Inc., a clinical-stage biotechnology firm, has signed an exclusive option-to-license agreement with the Population Council for the Nestorone/Testosterone Transdermal Gel (NES/T) for male contraception. If the option is exercised, Contraline will lead the global development and commercialization of NES/T,…
Vaxxas announced the start of a multi-center Phase I clinical trial for a vaccine targeting the pre-pandemic avian influenza strain H7N9, using its high-density microarray patch (HD-MAP) technology. Vaxxas has initiated a multi-center Phase I clinical trial of a pre-pandemic…
Medidata, a Dassault Systèmes brand and leader in clinical trial solutions for the life sciences industry, has announced a four-year extension of its partnership with the European Organisation for Research and Treatment of Cancer (EORTC). This extension aims to enhance…
Cellworks Group Inc., a leader in personalized therapy decision support and precision drug development, recently announced the results of a study demonstrating the accuracy of its biosimulation platform in predicting overall survival (OS) and chemotherapy benefits in two real-world cohorts…
Susan G. Komen®, the leading breast cancer organization, today applauds the new U.S. Food and Drug Administration (FDA) rule requiring mammography reports to include details about breast density. This federal mandate standardizes notification language, ensuring that all individuals across the…
HDS has launched Script Scan, a new addition to its Spotlight platform. This is the company’s first product specifically designed for pharmacies. Script Scan addresses the current challenges faced by pharmacy operators, including shrinking margins, limited staff, and intense market…
Inflammasome Therapeutics, a private company, has finished enrolling participants in a Phase I pharmacokinetics and safety study for its novel drug K9. This brain- and retina-penetrant compound is being evaluated for its potential in treating various neuroinflammatory and degenerative diseases,…
CEL-SCI Corporation (NYSE American: CVM) announced that it will present new data from its Phase 3 study of Multikine (Leukocyte Interleukin Injection) at the European Society for Medical Oncology (ESMO) 2024 Congress, taking place from September 13-17, 2024, in Barcelona,…
Paragon 28, Inc. (NYSE: FNA) is excited to introduce a new Right-Angle Drill for its APEX 3D™ Total Ankle Replacement System. This innovative tool is designed to enhance tibia preparation before implanting the APEX 3D™ tibia implant. The Right-Angle Drill…
Cellino Biotech, Inc. announced today that it has been awarded up to $25 million by the Advanced Research Projects Agency for Health (ARPA-H), a division of the U.S. Department of Health and Human Services. The funding will support the development…
Following our April 8, 2024, announcement, we’re excited to provide an update on our progress. The U.S. Food and Drug Administration (FDA) approved a Phase I/II clinical trial for DFP-10917 in combination with venetoclax (VEN) for patients with acute myeloid…